Pharnext SA
PAR:ALPHA

Watchlist Manager
Pharnext SA Logo
Pharnext SA
PAR:ALPHA
Watchlist
Price: 0.0002 EUR
Market Cap: 1.2k EUR

Net Margin
Pharnext SA

-21 040%
Current
-941 068.7%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-21 040%
=
Net Income
-31.6m
/
Revenue
150k

Net Margin Across Competitors

No Stocks Found

Pharnext SA
Glance View

Market Cap
1.2k EUR
Industry
Biotechnology

Pharnext SA develops and manufactures drugs for neurological diseases. The company is headquartered in Issy-Les-Moulineaux, Ile-De-France. The company went IPO on 2016-07-18. The firm is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The firm's prime focus is on neurodegenerative diseases and metabolic diseases.

ALPHA Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-21 040%
=
Net Income
-31.6m
/
Revenue
150k
What is the Net Margin of Pharnext SA?

Based on Pharnext SA's most recent financial statements, the company has Net Margin of -21 040%.

Back to Top